Blueprint Medicines Corp (BPMC)
90.76
-1.50
(-1.62%)
USD |
NASDAQ |
Apr 25, 16:00
90.76
0.00 (0.00%)
After-Hours: 20:00
Blueprint Medicines Shareholders Equity (Quarterly): 130.61M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 130.61M |
| September 30, 2023 | 202.61M |
| June 30, 2023 | 311.13M |
| March 31, 2023 | 414.30M |
| December 31, 2022 | 514.68M |
| September 30, 2022 | 640.31M |
| June 30, 2022 | 747.75M |
| March 31, 2022 | 881.67M |
| December 31, 2021 | 970.74M |
| September 30, 2021 | 1.247B |
| June 30, 2021 | 1.329B |
| March 31, 2021 | 1.400B |
| December 31, 2020 | 1.470B |
| September 30, 2020 | 1.32B |
| June 30, 2020 | 581.37M |
| March 31, 2020 | 682.93M |
| December 31, 2019 | 464.36M |
| September 30, 2019 | 516.34M |
| June 30, 2019 | 592.83M |
| Date | Value |
|---|---|
| March 31, 2019 | 344.21M |
| December 31, 2018 | 419.01M |
| September 30, 2018 | 489.30M |
| June 30, 2018 | 552.93M |
| March 31, 2018 | 570.87M |
| December 31, 2017 | 623.97M |
| September 30, 2017 | 341.24M |
| June 30, 2017 | 374.09M |
| March 31, 2017 | 188.22M |
| December 31, 2016 | 213.08M |
| September 30, 2016 | 97.71M |
| June 30, 2016 | 112.56M |
| March 31, 2016 | 129.66M |
| December 31, 2015 | 143.98M |
| September 30, 2015 | 158.14M |
| June 30, 2015 | 169.59M |
| March 31, 2015 | 24.72M |
| December 31, 2014 | 35.43M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
130.61M
Minimum
Dec 2023
1.470B
Maximum
Dec 2020
758.82M
Average
640.31M
Median
Sep 2022
Shareholders Equity (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -220.64M |
| Apellis Pharmaceuticals Inc | 194.52M |
| Ionis Pharmaceuticals Inc | 386.69M |
| Madrigal Pharmaceuticals Inc | 405.33M |
| Sarepta Therapeutics Inc | 859.34M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.049B |
| Total Liabilities (Quarterly) | 918.64M |
| Debt to Equity Ratio | 1.828 |
| Current Ratio | 3.761 |
| Net Debt Paydown Yield | -0.36% |